Literature DB >> 19223145

The influence of the characteristics of ischemic tissue lesions on ulcer healing time after infrainguinal bypass for critical leg ischemia.

Maria Söderström1, Pekka-Sakari Aho, Mauri Lepäntalo, Anders Albäck.   

Abstract

OBJECTIVE: Ulcer healing is a seldom reported outcome in studies of critical leg ischemia (CLI). The aim of this study was to analyze local factors affecting ulcer healing time after infrainguinal bypass surgery (IBS) for CLI Fontaine IV.
METHODS: In this prospective single center cohort study, 110 patients (113 legs) undergoing IBS due to CLI with ischemic tissue defects during year 2006 were followed prospectively for 1 year after the bypass. Ulcer location, duration, presence of gangrene, and the University of Texas wound classification (UTWCS) were determined at presentation. Healing time of the ischemic tissue defects, leg salvage, patency, and survival were calculated. The characteristics of the ischemic tissue lesions and patient comorbidities were analyzed to determine risk factors for adverse outcome.
RESULTS: Complete ulcer healing (+/-SE) was achieved in 74% +/- 5% of the legs 12 months after IBS. Median ulcer healing time was 186 days (range, 11 to >365 days). Leg salvage, secondary patency, and survival at 12 months were 87% +/- 3%, 82% +/- 4%, and 76% +/- 5%, respectively. Amputation-free survival with healed ulcers was attained in 55% at 12 months. Ischemic tissue lesions located in the mid- and hindfoot had significantly prolonged ulcer healing time (hazard ratio [HR] 0.4, 95% confidence interval [CI] 0.1 to 0.9, P = .044). None of the UTWCS classes predicted either ulcer healing time or leg salvage. Median ulcer duration before IBS was 68 days, range, 6 to 1154 days. Ulcer duration did not correlate with ulcer healing time (Spearman r = 0.138, P = .267). Ischemic ulcers with gangrene were not associated with prolonged ulcer healing time (P = .353).
CONCLUSION: The location of the ischemic tissue lesions influences ulcer healing time. According to our study UTWCS can be used as descriptive classification of ischemic ulcers but it does not predict the ulcer healing time or leg salvage after infrainguinal bypass surgery.

Entities:  

Mesh:

Year:  2009        PMID: 19223145     DOI: 10.1016/j.jvs.2008.11.045

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

1.  Early-phase wound healing and long-term outcomes of a selective endovascular-first approach for treating Rutherford 5 critical limb ischemia with infrainguinal lesions.

Authors:  Kentaro Inoue; Toshihiro Onohara; Keita Mikasa; Tadashi Furuyama
Journal:  Surg Today       Date:  2016-04-18       Impact factor: 2.549

2.  The role of foot collateral vessels on angiosome-oriented revascularization.

Authors:  César Varela; Francisco Acín; Joaquin De Haro; Ignacio Michel
Journal:  Ann Transl Med       Date:  2017-11

3.  The role of chronic kidney disease as a predictor of outcome after revascularisation of the ulcerated diabetic foot.

Authors:  M Venermo; F Biancari; E Arvela; M Korhonen; M Söderström; K Halmesmäki; A Albäck; M Lepäntalo
Journal:  Diabetologia       Date:  2011-08-16       Impact factor: 10.122

4.  Wound location is independently associated with adverse outcomes following first-time revascularization for tissue loss.

Authors:  Jeremy D Darling; Thomas F X O'Donnell; Giap H Vu; Anthony V Norman; Emily St John; Lars Stangenberg; Mark C Wyers; Allen D Hamdan; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2020-08-29       Impact factor: 4.268

5.  Amputations and socioeconomic position among persons with diabetes mellitus, a population-based register study.

Authors:  Maarit Venermo; Kristiina Manderbacka; Tuija Ikonen; Ilmo Keskimäki; Klas Winell; Reijo Sund
Journal:  BMJ Open       Date:  2013-04-08       Impact factor: 2.692

6.  Results of infrapopliteal endovascular procedures performed in diabetic patients with critical limb ischemia and tissue loss from the perspective of an angiosome-oriented revascularization strategy.

Authors:  Francisco Acín; César Varela; Ignacio López de Maturana; Joaquín de Haro; Silvia Bleda; Javier Rodriguez-Padilla
Journal:  Int J Vasc Med       Date:  2014-01-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.